BDH2 Antibody

What is BDH2 and what cellular functions does it regulate?

BDH2 (3-hydroxybutyrate Dehydrogenase, Type 2) is a NAD(H)-dependent dehydrogenase/reductase that preferentially acts on cyclic substrates. It catalyzes the stereoselective conversion of 4-oxo-L-proline to cis-4-hydroxy-L-proline, which likely serves as a detoxification mechanism for ketoprolines. More significantly, BDH2 mediates the formation of 2,5-dihydroxybenzoate (2,5-DHBA), a siderophore that chelates free cytoplasmic iron and associates with LCN2, regulating iron transport and homeostasis while protecting cells against oxidative stress. Additionally, BDH2 functions as a tumor suppressor in gastric cancer by regulating intracellular reactive oxygen species (ROS) levels and mediating the PI3K/Akt/mTOR signaling pathway . The iron-siderophore complex is also imported into mitochondria, providing an essential iron source for mitochondrial metabolic processes, particularly heme synthesis.

What types of BDH2 antibodies are available for research?

Several types of BDH2 antibodies are available for research applications, including polyclonal and monoclonal variants with different host species and targeting specifications. Polyclonal antibodies raised in rabbit, mouse, and goat are common, with various reactivity profiles across human, mouse, rat, horse, bat, cow, and rabbit samples . Monoclonal antibodies are also available, including specifically labeled clones like 3G10 and 4G4 that target particular regions of BDH2. Conjugated BDH2 antibodies are available with HRP, biotin, or FITC for specialized applications, while unconjugated versions remain the most commonly used in standard laboratory techniques . Researchers can select antibodies targeting specific amino acid regions of BDH2, such as AA 1-245, AA 92-103, and AA 143-192, depending on the experimental requirements and target epitope accessibility.

How do I select the appropriate BDH2 antibody for my specific research application?

Selecting the appropriate BDH2 antibody requires consideration of several experimental factors. First, determine your target species - whether human, mouse, rat, or others - and verify the antibody's cross-reactivity profile with your experimental model. Second, consider the intended application; different antibodies are optimized for specific techniques such as Western blotting, immunohistochemistry, ELISA, flow cytometry, or immunofluorescence . The specific epitope region targeted is crucial for certain applications; for instance, antibodies targeting AA 1-245 of BDH2 are suitable for multiple applications including ELISA and IHC, while those targeting the internal region or specific segments like AA 92-103 may be more suitable for specialized applications . Finally, consider the clonality needed - monoclonal antibodies provide higher specificity to a single epitope, making them ideal for discriminating between closely related proteins, while polyclonal antibodies recognize multiple epitopes and often provide stronger signals.

What protocols should be followed for immunohistochemistry staining using BDH2 antibodies?

For immunohistochemistry (IHC) with BDH2 antibodies, tissue sections should be cut to 3-μm thickness, deparaffinized, and rehydrated. Incubate sections with 3% hydrogen peroxide for 1 hour to block endogenous peroxidase activity, followed by antigen retrieval. For primary antibody incubation, use BDH2 antibody at an optimized dilution (1:100 to 1:500, depending on the specific antibody) and incubate overnight at 4°C . Apply an appropriate secondary antibody (such as ZB-2305) for 1 hour at room temperature, followed by developing with 3,3′-diaminobenzidine (DAB) reagent for the peroxidase reaction and counterstaining with hematoxylin . For evaluation, have two independent pathologists assess the intensity of BDH2 staining in a blinded manner, using established scoring methods. For human tissue samples, kidney tissue often shows good BDH2 expression, while skeletal muscle typically displays lower expression, making these useful positive and comparative controls, respectively .

How should Western blotting with BDH2 antibodies be optimized for different sample types?

For optimizing Western blotting with BDH2 antibodies, begin with sample preparation: use RIPA buffer with protease inhibitors for tissue lysates or cell extracts. Load 20-40 μg of protein per lane after quantification. During SDS-PAGE, use 12-15% gels as BDH2 has a predicted molecular weight of 27 kDa . For transfer, use PVDF membranes and optimize transfer conditions (25V for 1.5 hours) to ensure complete protein transfer. Block membranes with 5% non-fat milk or BSA in TBST for 1 hour at room temperature. For primary antibody incubation, use BDH2 antibody at a dilution of 0.4-1 μg/mL (optimally determined for each antibody) and incubate overnight at 4°C . Wash thoroughly with TBST before applying HRP-conjugated secondary antibody for 1 hour. For detection, use enhanced chemiluminescence reagents and expose to X-ray film or digital imager with appropriate exposure times. When analyzing human samples, kidney tissue lysate serves as a good positive control as it shows strong BDH2 expression . For challenging samples with low BDH2 expression, consider longer exposure times or signal amplification methods.

What are the recommended protocols for using BDH2 antibodies in cell-based assays?

For cell-based assays with BDH2 antibodies, immunocytochemistry/immunofluorescence (ICC/IF) protocols should begin with fixation of cells using 4% paraformaldehyde (PFA) for 15 minutes at room temperature, followed by permeabilization with 0.1% Triton X-100 for 10 minutes . Block with 1-5% BSA or normal serum for 30-60 minutes. Apply the primary BDH2 antibody at an optimized dilution (typically 1:100 to 1:500) and incubate overnight at 4°C or for 1-2 hours at room temperature. After washing, apply fluorophore-conjugated secondary antibodies for 1 hour at room temperature, protected from light. Counterstain nuclei with DAPI and mount with anti-fade mounting medium. For flow cytometry applications, trypsinize adherent cells or collect suspension cells, fix with 2-4% PFA, permeabilize if targeting intracellular BDH2, and incubate with BDH2 antibody at optimized concentrations. Both monoclonal antibodies like clones 3G10 and 4G4 have been validated for these applications . U-251 MG (human brain glioma cell line) has been confirmed to express BDH2 and can serve as a positive control for cellular assays .

How can BDH2 antibodies be utilized to investigate the role of BDH2 in cancer progression?

BDH2 antibodies can be employed to investigate BDH2's role in cancer progression through multiple sophisticated approaches. Researchers can perform comprehensive immunohistochemical analysis of paired cancer tissues (such as gastric cancer) and adjacent normal tissues to evaluate BDH2 expression patterns and correlate them with clinicopathological features and patient prognosis . For mechanistic studies, BDH2 antibodies can be used in co-immunoprecipitation assays to examine BDH2's interactions with key molecules in cancer-related pathways, such as the Keap1-Nrf2 axis, which regulates oxidative stress responses in cancer cells . Western blotting with BDH2 antibodies can be conducted after experimental manipulation of BDH2 expression (overexpression or knockdown) to monitor downstream effects on signaling pathways, particularly the PI3K/Akt/mTOR pathway that regulates cell growth and survival . Researchers can combine BDH2 immunostaining with markers of apoptosis (cleaved caspase-3) and autophagy (LC3B) to evaluate BDH2's impact on these cellular processes in cancer tissues . Additionally, BDH2 antibodies can be used in chromatin immunoprecipitation (ChIP) assays to investigate potential transcriptional regulatory mechanisms controlling BDH2 expression in different cancer types.

What methodologies are recommended for investigating BDH2's role in iron metabolism using BDH2 antibodies?

To investigate BDH2's role in iron metabolism, researchers should employ a multi-faceted approach combining BDH2 antibodies with iron detection methods. Begin with subcellular fractionation of cells with differential BDH2 expression (normal vs. knockdown/overexpression), followed by Western blotting with BDH2 antibodies to confirm localization patterns in cytosolic and mitochondrial fractions. Use iron colorimetric assays to quantify total cellular iron levels in conjunction with BDH2 expression analysis . Implement co-immunoprecipitation with BDH2 antibodies to identify protein-protein interactions between BDH2 and iron transport/storage proteins, such as LCN2, transferrin receptor, and ferritin. Perform immunofluorescence co-localization studies using BDH2 antibodies alongside iron transporters and storage protein markers to visualize spatial relationships within cells. Utilize proximity ligation assays (PLA) with BDH2 antibodies to detect and quantify specific molecular interactions between BDH2 and iron-related proteins with nanometer resolution. For functional assessment, measure 2,5-DHBA production (the siderophore mediated by BDH2) through mass spectrometry while validating BDH2 expression levels via Western blotting. These combined approaches provide comprehensive insight into how BDH2 regulates iron transport, homeostasis, and utilization in cellular systems.

How can one design experiments to investigate BDH2's involvement in oxidative stress pathways using BDH2 antibodies?

To investigate BDH2's involvement in oxidative stress pathways, design experiments beginning with establishing cell models with altered BDH2 expression through transfection of BDH2 overexpression vectors (pcDNA3.1-BDH2) or siRNA-mediated knockdown, confirming expression changes via Western blotting using BDH2 antibodies . Measure intracellular ROS levels using fluorescent probes (such as DCFH-DA or MitoSOX) in cells with differential BDH2 expression under both basal conditions and following oxidative stress inducers like H₂O₂ or tBHP. Analyze the Keap1-Nrf2 pathway by conducting immunoprecipitation with BDH2 antibodies to examine BDH2-Keap1 interactions, followed by Western blotting for Nrf2 to assess degradation status . Perform ubiquitination assays after BDH2 manipulation to determine its effect on Nrf2 ubiquitination and subsequent proteasomal degradation. Use chromatin immunoprecipitation (ChIP) assays to evaluate Nrf2 binding to antioxidant response elements (AREs) in the promoters of antioxidant genes under different BDH2 expression conditions. Assess mitochondrial function parameters (membrane potential, ATP production, oxygen consumption rate) in conjunction with BDH2 expression analysis. Finally, measure the expression of downstream antioxidant genes (such as SOD, catalase, GPx) via RT-qPCR and Western blotting after BDH2 manipulation to establish functional consequences of BDH2-mediated oxidative stress regulation.

What are common troubleshooting strategies for false-negative results when using BDH2 antibodies in immunohistochemistry?

When encountering false-negative results in BDH2 immunohistochemistry, several methodological adjustments can be implemented. First, optimize the antigen retrieval process, as inadequate retrieval is a primary cause of false-negative results; try various methods (heat-induced epitope retrieval using citrate buffer pH 6.0 or EDTA buffer pH 9.0) with different durations (10-30 minutes). Adjust the BDH2 antibody concentration; try a range of dilutions (1:50 to 1:500) to determine the optimal working concentration for your specific tissue . Extend the primary antibody incubation time to overnight at 4°C if shorter incubations are insufficient. Test different detection systems, comparing DAB-based chromogenic detection with amplification systems or fluorescent-based methods. Verify antibody functionality using positive control tissues known to express BDH2, such as human kidney tissue, which consistently shows good BDH2 expression . Consider tissue-specific fixation issues; overfixation in formalin can mask epitopes, so testing samples with different fixation conditions may be necessary. Finally, evaluate endogenous peroxidase or phosphatase blocking efficiency and extend blocking times if background interference is suspected. For particularly challenging samples, signal amplification systems like tyramide signal amplification (TSA) may significantly enhance detection sensitivity.

How can non-specific binding be minimized when using BDH2 antibodies?

To minimize non-specific binding when using BDH2 antibodies, implement a comprehensive optimization protocol. Begin with thorough blocking by extending the blocking step to 1-2 hours using 5% BSA or 10% normal serum from the same species as the secondary antibody . Optimize antibody dilutions by testing a range of concentrations to find the minimum effective concentration that provides specific staining while minimizing background. Increase washing steps between antibody incubations, using at least three 5-10 minute washes with gentle agitation in PBS-T or TBS-T. When selecting BDH2 antibodies, prioritize those with higher specificity, such as monoclonal antibodies (like clones 3G10 or 4G4) or highly purified polyclonal antibodies (>95% Protein G purified) . For immunohistochemistry applications, include an avidin/biotin blocking step if using a biotin-based detection system to reduce endogenous biotin interference. Perform pre-adsorption controls by pre-incubating the BDH2 antibody with purified BDH2 protein prior to staining, which should eliminate specific staining but not non-specific binding. Add 0.1-0.3% Triton X-100 to the antibody diluent to reduce hydrophobic interactions causing non-specific binding. Finally, consider including additional protein carriers (such as 0.1-0.5% gelatin or casein) in the antibody diluent to further reduce non-specific interactions.

What current methodologies leverage BDH2 antibodies to study nasopharyngeal carcinoma?

Current methodologies for studying nasopharyngeal carcinoma (NPC) using BDH2 antibodies encompass a comprehensive experimental pipeline. Researchers begin with expression analysis by performing real-time RT-PCR to quantify BDH2 transcript levels and immunohistochemistry staining using BDH2 antibodies (typically at 1:1000 dilution) to visualize protein expression patterns in NPC tissue sections compared to normal nasopharyngeal tissues . For functional studies, stable cell lines with altered BDH2 expression are established through transfection with BDH2 expression vectors or siRNA, with verification of expression changes via Western blotting using BDH2 antibodies. Cell proliferation, migration, and invasion capabilities are subsequently assessed using MTT assays, wound-healing assays, and Transwell assays, respectively, in cells with differential BDH2 expression . To elucidate molecular mechanisms, cDNA microarray analysis is conducted to profile genes regulated by BDH2 restoration in NPC cells, followed by validation of key targets through RT-qPCR and Western blotting. Given BDH2's involvement in iron metabolism, iron colorimetric assays are employed to determine iron levels in NPC cells with varying BDH2 expression, providing insights into how iron homeostasis may contribute to NPC pathogenesis . These combined approaches have revealed important functional roles of BDH2 in NPC development and progression.

How can advanced computational approaches enhance BDH2 antibody design for therapeutic applications?

Advanced computational approaches can significantly enhance BDH2 antibody design for therapeutic applications through several sophisticated methodologies. Deep learning models like IgDesign represent a cutting-edge approach for antibody complementarity-determining region (CDR) design, allowing for the creation of antibodies with improved binding characteristics to target specific epitopes on BDH2 . These models can design heavy chain CDR3 (HCDR3) or all three heavy chain CDRs (HCDR123) using native backbone structures of antibody-antigen complexes, along with antigen and antibody framework sequences as context . Surface plasmon resonance (SPR) screening can then be employed to validate these computationally designed antibodies for binding against BDH2, enabling the selection of candidates with optimal affinity profiles. In some cases, this approach has yielded improved affinities over clinically validated reference antibodies . For therapeutic applications targeting BDH2 in cancer (where it functions as a tumor suppressor) or in iron metabolism disorders, structure-based antibody design utilizing crystallographic data of BDH2 can further refine epitope targeting to modulate specific functions. These computational approaches, combined with experimental validation, represent a transformative strategy for accelerating therapeutic antibody development with applications in both de novo antibody design and lead optimization for BDH2-targeted therapies.

What novel applications are emerging for BDH2 antibodies in cancer immunotherapy research?

Emerging applications for BDH2 antibodies in cancer immunotherapy research represent a frontier area with several promising directions. Given BDH2's established role as a tumor suppressor that regulates ROS levels and the PI3K/Akt/mTOR pathway in gastric cancer, researchers are exploring antibody-drug conjugates (ADCs) targeting cancer cells with aberrant BDH2 expression patterns . These ADCs combine BDH2 antibodies with cytotoxic payloads to selectively deliver therapeutic agents to cancer cells. Another innovative approach involves developing bispecific antibodies that simultaneously target BDH2 and immune checkpoint molecules (such as PD-1 or CTLA-4), potentially enhancing immune recognition of cancer cells with altered BDH2 expression. For cancers where BDH2 is downregulated, such as gastric cancer, researchers are investigating indirect approaches using BDH2 antibodies to identify and target upstream regulators or downstream effectors in the BDH2 signaling pathway . BDH2 antibodies are also being utilized to develop companion diagnostics for stratifying patients who might benefit from therapies targeting the PI3K/Akt/mTOR pathway based on their BDH2 expression profile. Additionally, the connection between BDH2, iron metabolism, and cancer progression offers opportunities for developing combination therapies that simultaneously target BDH2-related pathways and iron dependency in cancer cells, with BDH2 antibodies serving as both research tools and potential therapeutic agents.

How can BDH2 antibodies be utilized to investigate the relationship between iron metabolism and neurodegenerative diseases?

BDH2 antibodies offer valuable tools for investigating the complex relationship between iron metabolism and neurodegenerative diseases through multiple experimental approaches. Researchers can perform comparative immunohistochemistry with BDH2 antibodies on brain tissue from patients with various neurodegenerative conditions (Alzheimer's, Parkinson's, ALS) versus age-matched controls to map BDH2 expression patterns in affected regions . Co-localization studies combining BDH2 antibodies with markers for iron accumulation, oxidative stress, and neurodegeneration can reveal spatial relationships between BDH2 expression and pathological hallmarks. Primary neuronal cultures or neural organoids with manipulated BDH2 expression (verified by Western blotting with BDH2 antibodies) can be subjected to iron overload or chelation to assess neuroprotective or neurotoxic effects. BDH2's role in synthesizing the siderophore 2,5-DHBA suggests potential involvement in neuronal iron homeostasis; researchers can quantify 2,5-DHBA levels in conjunction with BDH2 protein expression in brain regions affected by neurodegeneration. Animal models of neurodegenerative diseases can be analyzed for temporal changes in BDH2 expression using immunohistochemistry and Western blotting with BDH2 antibodies, correlating these changes with disease progression. Additionally, the relationship between BDH2, mitochondrial function, and oxidative stress in neurons can be explored using BDH2 antibodies in combination with mitochondrial functional assays, potentially revealing new therapeutic targets for neurodegenerative conditions associated with iron dysregulation and oxidative damage.

What experimental designs could investigate the potential role of BDH2 in cellular resistance to oxidative stress-inducing therapeutics?

To investigate BDH2's potential role in cellular resistance to oxidative stress-inducing therapeutics, researchers should implement comprehensive experimental designs leveraging BDH2 antibodies as critical reagents. Begin by establishing a panel of cancer cell lines with varying endogenous BDH2 expression levels, confirmed via Western blotting and immunofluorescence with BDH2 antibodies . Generate stable cell lines with BDH2 overexpression or knockdown using appropriate vectors or siRNA/shRNA respectively, verifying manipulation via Western blotting with BDH2 antibodies . Conduct dose-response assays exposing these modified cell lines to oxidative stress-inducing therapeutics (e.g., platinum compounds, anthracyclines, radiation therapy) and measure cell viability, apoptosis, and ROS accumulation. Perform comprehensive molecular analyses including Western blotting for key proteins in the Keap1-Nrf2 pathway (Keap1, Nrf2, downstream antioxidant enzymes) and the PI3K/Akt/mTOR pathway (phosphorylated and total forms) to establish mechanistic connections between BDH2 expression and therapeutic resistance . Use co-immunoprecipitation with BDH2 antibodies to identify novel protein interactions in resistant versus sensitive cells. Analyze clinical samples from patients with differential responses to oxidative stress-inducing therapies using BDH2 immunohistochemistry to correlate expression with treatment outcomes . Finally, test combination strategies using BDH2-targeting approaches (e.g., BDH2 inhibitors) alongside oxidative stress-inducing therapeutics in preclinical models to evaluate potential synergistic effects for overcoming resistance, validating BDH2 modulation via Western blotting with BDH2 antibodies.

Table 7.1: Recommended Dilutions and Applications for Different Types of BDH2 Antibodies

Table 7.2: Experimental Controls for BDH2 Antibody Applications

Table 7.3: BDH2 Expression Correlation with Clinical Parameters in Gastric Cancer

What are the most critical knowledge gaps in BDH2 research that require antibody-based investigations?

Despite significant advances in understanding BDH2's functions, several critical knowledge gaps remain that require sophisticated antibody-based investigations. The tissue-specific expression patterns and subcellular localization of BDH2 isoforms across different pathological conditions need comprehensive mapping using validated BDH2 antibodies with defined epitope specificities . The temporal dynamics of BDH2 expression during disease progression, particularly in cancer and neurodegenerative disorders, require longitudinal studies with consistent antibody-based detection methods . The post-translational modifications of BDH2 that may regulate its enzymatic activity and protein-protein interactions remain largely unexplored and could be investigated using modified-residue-specific BDH2 antibodies. The intricate relationship between BDH2's dual functions in ketone body metabolism and iron homeostasis needs clarification through co-immunoprecipitation studies using BDH2 antibodies to identify novel interaction partners . The mechanisms regulating BDH2 expression at transcriptional and post-transcriptional levels across different cellular contexts require investigation, potentially using BDH2 antibodies in chromatin immunoprecipitation sequencing (ChIP-seq) studies. Additionally, the potential role of BDH2 in cellular responses to various therapeutic interventions, particularly those inducing oxidative stress, needs systematic evaluation using BDH2 antibodies in preclinical and clinical samples . Addressing these knowledge gaps will significantly advance our understanding of BDH2's biological functions and therapeutic potential.